デフォルト表紙
市場調査レポート
商品コード
1004267

自動注射器の世界市場

The global auto injector market by product type, therapy type, indication, route of distribution, end user & regions

出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 216 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
自動注射器の世界市場
出版日: 2021年05月04日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 216 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の自動注射器市場は、2019年から2027年にかけて18.2%のCAGRで推移し、2019年の401億米ドルから2027年には1,531億米ドルに達すると予測されています。同市場の主な成長要因には、標的療法の普及、アナフィラキシーの発生率の上昇、薬剤の自己投与への嗜好の高まり、使い勝手の良さ、規制当局の承認数の増加、自動注射器のジェネリック版の利用可能性、有利な償還や政府の支援、技術の進歩などが挙げられます。また、生物学的製剤の特許満了は市場の成長機会になると考えられています。

COVID-19のパンデミックは、世界的な医療危機をもたらし、ほとんどの地域で医療提供体制の変化を引き起こしています。さらに、臨床試験の募集が滞ったことで、新しい治療法の導入が遅れており、2020年初頭の自動注射器市場にマイナスの影響を与えた可能性があります。しかし、効果的なホームケアや遠隔モニタリングへの需要により、患者が病院を訪れることなく、便利かつ簡単に慢性疾患やアレルギーを管理することができ、予測期間中の市場へのプラスの影響が見込まれています。

当レポートは、世界の自動注射器市場について調査しており、市場の成長および抑制要因、機会や課題、治療・タイプ・投与経路・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 成長要因
    • 抑制要因
    • 機会
    • 課題
  • 自動注射器市場のCOVID-19による影響

第6章 業界考察

  • イントロダクション
  • 業界の動向

第7章 自動注射器市場:治療別(2020-2027)

  • 関節リウマチ
  • 糖尿病
  • 多発性硬化症
  • アナフィラキシー
  • その他

第8章 自動注射器市場:タイプ別(2020-2027)

  • 使い捨て自動注射器
  • 再利用可能な自動注射器

第9章 自動注射器市場:投与経路別(2020-2027)

  • 皮下
  • 筋肉内

第10章 自動注射器市場:エンドユーザー別(2020-2027)

  • 在宅ケア
  • 病院および診療所
  • 外来

第11章 自動注射器市場:地域別(2020-2027)

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • ラテンアメリカ
  • 中東とアフリカ

第12章 競合情勢

  • イントロダクション
  • 競合の現状と動向
    • 製品発売
    • 提携、協業、契約
    • 買収
    • 拡張
    • その他の開発

第13章 企業プロファイル

  • Abbvie Inc.
  • Amgen
  • Elli Lilly and Company
  • Mylan
  • Ypsomed
  • Becton, Dickinson, and Company
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries
  • Antares Pharma, Inc.
  • Merck KGAA
  • Meridian Medical Technologies, Inc.
  • Roche
  • Bespak
  • Bayer AG
  • Bristol-Myers Squibb Company
  • SHL Medical
  • Haselmeter
  • Owen Mumford
  • Ravimed

第14章 付録

  • 1)ディスカッションガイド
  • 2)利用可能なカスタマイズ
  • 3)関連レポート
目次

The global autoinjectors market is projected to reach USD 153.1 billion by 2027 from USD 40.1 billion in 2019, at a CAGR of 18.2% from 2019 to 2027. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favourable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices. Some of the key players operating in the autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Moreover, the slowdown in clinical trial recruitment has delayed the introduction of new therapies. These factors could have had a negative impact on the autoinjectors market, especially with their use in healthcare institutions in early 2020. However, the pandemic's overall effect on the autoinjectors is considered positive, especially in the forecast period, due to several factors. Firstly, the demand for effective home care and remote monitoring has increased the relevance of autoinjectors for patients to conveniently and easily manage chronic illnesses and allergies without visiting the hospital. This has been especially true in the case of diabetes, Crohn's disease, a rheumatoid arthritis patient relying on prefilled syringes and autoinjectors to manage their condition at home.

The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anaemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest share of autoinjectors market. The large share of this segment is mainly attributed to its high prevalence. The increasing incidence of RA fuels the demand for autoinjectors for this therapy segment. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US are affected annually by some form of arthritis, RA, gout, lupus, or fibromyalgia.

Based on type, the autoinjectors market is segmented into reusable and disposable autoinjectors. In 2018, the disposable autoinjectors segment accounted for the largest share of the global autoinjectors market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

Based on route of administration, the autoinjectors market is segmented intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anaemia, and cancer. The subcutaneous segment accounted for the largest share and it is expected to witness fastest growth during the forecast period. The large share of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. The home care settings segment accounted for the largest share of the autoinjectors market in 2018. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Premium Insights

5. Market Overview

  • 1) Introduction
  • 2) Market Dynamics
    • i. Drivers
    • ii. Restraints
    • iii. Opportunities
    • iv. Challenges
  • 3) COVID-19 Impact of the Autoinjectors Market

6. Industry Insights

  • 1) Introduction
  • 2) Industry Trends

7. Autoinjectors Market, By Therapy, 2020-2027 (USD Million)

  • 1) Rheumatoid Arthritis
  • 2) Diabetes
  • 3) Multiple Sclerosis
  • 4) Anaphylaxis
  • 5) Other Therapies

8. Autoinjectors Market, By Type, 2020-2027 (USD Million)

  • 1) Disposable Autoinjectors
  • 2) Reusable Autoinjectors

9. Autoinjectors Market, By Route of Administration, 2020-2027 (USD Million)

  • 1) Subcutaneous
  • 2) Intramuscular

10. Autoinjectors Market, By End User, 2020-2027 (USD Million)

  • 1) Home Care
  • 2) Hospitals & Clinics
  • 3) Ambulatory Care Settings

11. Autoinjectors Market, By Geography, 2020-2027 (USD Million)

  • 1) North America
    • i. US
    • ii. Canada
  • 2) Europe
    • i. Germany
    • ii. UK
    • iii. France
    • iv. Italy
    • v. Spain
    • vi. Rest of Europe
  • 3) Asia-Pacific
    • i. China
    • ii. Japan
    • iii. India
    • iv. Rest of Asia-Pacific
  • 4) Latin America
  • 5) Middle East and Africa

12. Competitive Landscape

  • 1) Introduction
  • 2) Competitive Situation and Trends
    • i. Product Launches
    • ii. Partnerships, Collaborations, and Agreements
    • iii. Acquisitions
    • iv. Expansions
    • v. Other Developments

13. Company Profiles

  • 1) Abbvie Inc.
  • 2) Amgen
  • 3) Elli Lilly and Company
  • 4) Mylan
  • 5) Ypsomed
  • 6) Becton, Dickinson, and Company
  • 7) Glaxosmithkline Plc.
  • 8) Johnson & Johnson
  • 9) Teva Pharmaceutical Industries
  • 10) Antares Pharma, Inc.
  • 11) Merck KGAA
  • 12) Meridian Medical Technologies, Inc.
  • 13) Roche
  • 14) Bespak
  • 15) Bayer AG
  • 16) Bristol-Myers Squibb Company
  • 17) SHL Medical
  • 18) Haselmeter
  • 19) Owen Mumford
  • 20) Ravimed

14. Appendix

  • 1) Discussion Guide
  • 2) Available Customizations
  • 3) Related Reports